Adicet Bio (ACET) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET:
- Adicet Bio’s Promising Off-the-Shelf Cell Therapy Garners Buy Rating Due to Positive Clinical Outcomes and Strong Market Position
- Adicet Bio price target raised to $8 from $7 at Guggenheim
- Adicet Bio Receives Nasdaq Extension for Compliance
- Adicet Bio announces $80M registered direct offering
- Adicet Bio Announces Major Stock Offering Agreement